Mariam Anees
Quaid-i-Azam University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mariam Anees.
Cancer | 2013
Dietmar Pils; Peter Horak; Petr Vanhara; Mariam Anees; Michaela Petz; Angela Alfanz; Alfred Gugerell; Michael Wittinger; Andreas Gleiss; Veronika Auner; Dan Tong; Robert Zeillinger; Elena-Ioana Braicu; Jalid Sehouli; Michael Krainer
Current prognostic information in ovarian cancer is based on tumor stage, tumor grade, and postoperative tumor size. Reliable molecular prognostic markers are scarce. In this article, the authors describe epigenetic events in a frequently deleted region on chromosome 8p22 that influence the expression of tumor suppressor candidate 3 (TUSC3), a putative tumor suppressor gene in ovarian cancer.
Scientific Reports | 2015
Peter Horak; Erwin Tomasich; Petr Vaňhara; Kateřina Kratochvílová; Mariam Anees; Maximilian Marhold; Christof E. Lemberger; Marion Gerschpacher; Reinhard Horvat; Maria Sibilia; Dietmar Pils; Michael Krainer
Prostate cancer is the most prevalent cancer in males in developed countries. Tumor suppressor candidate 3 (TUSC3) has been identified as a putative tumor suppressor gene in prostate cancer, though its function has not been characterized. TUSC3 shares homologies with the yeast oligosaccharyltransferase (OST) complex subunit Ost3p, suggesting a role in protein glycosylation. We provide evidence that TUSC3 is part of the OST complex and affects N-linked glycosylation in mammalian cells. Loss of TUSC3 expression in DU145 and PC3 prostate cancer cell lines leads to increased proliferation, migration and invasion as well as accelerated xenograft growth in a PTEN negative background. TUSC3 downregulation also affects endoplasmic reticulum (ER) structure and stress response, which results in increased Akt signaling. Together, our findings provide first mechanistic insight in TUSC3 function in prostate carcinogenesis in general and N-glycosylation in particular.
Clinical Cancer Research | 2011
Michael Wittinger; Petr Vanhara; Ahmed El-Gazzar; Bettina Savarese-Brenner; Dietmar Pils; Mariam Anees; Thomas W. Grunt; Maria Sibilia; Martin Holcmann; Reinhard Horvat; Michael Schemper; Robert Zeillinger; Christian Schöfer; Helmut Dolznig; Peter Horak; Michael Krainer
Purpose: Although prognostic and predictive factors in ovarian cancer have been extensively studied for decades, only few have been identified and introduced to clinical practice. Here, we evaluate hVps37A (HCRP1) as a possible novel predictive marker for ovarian cancer. hVps37A was originally described as a member of the membrane-trafficking ESCRT-I complex mediating the internalization and degradation of ubiquitinated membrane receptors. Experimental Design: We analyzed an ovarian cancer tissue microarray for HCRP1, EGFR, and HER2 expression. We used a tetracycline inducible ovarian cancer cell culture model to show the effects of hVps37A knockdown in vitro and in vivo. In addition, we studied the effects of epidermal growth factor receptor (EGFR) inhibitors cetuximab and lapatinib on ovarian cancer cells under conditions of hVps37A knockdown. Results: We find that hVps37A is significantly downregulated in ovarian cancer and modifies the prognostic value of EGFR and HER2 expression. In addition, hVps37A downregulation in ovarian cancer cells leads to cytoplasmic pEGFR retention and hyperactivation of downstream pathways and is associated with enhanced xenograft growth in nude mice and invasion of the collagen matrix. Furthermore, due to subsequent sustained Akt- and MAPK-pathway activation, hVps37A-deficient cells become irresponsive to inhibition by the therapeutic antibody cetuximab. Conclusion: We propose that hVps37A status could become a novel prognostic and therapeutic marker for EGFR or HER2 driven tumors. Clin Cancer Res; 17(24); 7816–27. ©2011 AACR.
International Journal of Cancer | 2015
Kateřina Kratochvílová; Peter Horak; Milan Ešner; Karel Souček; Dietmar Pils; Mariam Anees; Erwin Tomasich; František Dráfi; Veronika Jurtíková; Aleš Hampl; Michael Krainer; Petr Vaňhara
Ovarian cancer is one of the most common malignancies in women and contributes greatly to cancer‐related deaths. Tumor suppressor candidate 3 (TUSC3) is a putative tumor suppressor gene located at chromosomal region 8p22, which is often lost in epithelial cancers. Epigenetic silencing of TUSC3 has been associated with poor prognosis, and hypermethylation of its promoter provides an independent biomarker of overall and disease‐free survival in ovarian cancer patients. TUSC3 is localized to the endoplasmic reticulum in an oligosaccharyl tranferase complex responsible for the N‐glycosylation of proteins. However, the precise molecular role of TUSC3 in ovarian cancer remains unclear. In this study, we establish TUSC3 as a novel ovarian cancer tumor suppressor using a xenograft mouse model and demonstrate that loss of TUSC3 alters the molecular response to endoplasmic reticulum stress and induces hallmarks of the epithelial‐to‐mesenchymal transition in ovarian cancer cells. In summary, we have confirmed the tumor‐suppressive function of TUSC3 and identified the possible mechanism driving TUSC3‐deficient ovarian cancer cells toward a malignant phenotype.
Gynecologic Oncology | 2010
Ahmed El-Gazzar; Michael Wittinger; Paul Perco; Mariam Anees; Reinhard Horvat; Wolfgang Mikulits; Thomas W. Grunt; Bernd Mayer; Michael Krainer
OBJECTIVE In the current study, we aimed to investigate the role of the long isoform of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme (FLICE)-like inhibitory protein (c-FLIP(L)) in ovarian cancer (OC) development by using RNA interference (RNAi) in vitro and in vivo. METHODS TRAIL-resistant human OC cell lines were genetically manipulated by RNAi-mediated suppression of c-FLIP(L). Subsequently, the genetic alteration that was introduced into the various OC cell lines was characterized in vitro and in vivo. RESULTS We previously showed that about 40% of OC patients express high levels of c-FLIP(L), and that natural killer (NK) cells mediated immunosurveillance in OC. In the present study, we observed that the knockdown of c-FLIP(L) in human OC cell lines not only enhanced their sensitivity to TRAIL-mediated apoptosis, but also inhibited their migratory phenotype in a TRAIL-dependent manner in vitro. Shutdown of c-FLIP(L) in OC cells significantly decreased tumor development by induction of apoptosis and reduction of proliferation in vivo. Importantly, the knockdown of c-FLIP(L) particularly inhibited the invasion of OC cells into the peritoneal cavity, which might be due to high expression of TRAIL by NK cells and NK-cell mediated immunosurveillance. CONCLUSION These data demonstrate that c-FLIP(L) exhibits multiple functions in OC cells: first by concomitantly evading the natural immunity mediated by TRAIL-induced cell death, and second by augmenting cell motility and invasion in vivo. Our findings indicate that c-FLIP(L) regulates sensitivity of OC to TRAIL-mediated apoptosis and offers possible therapeutical implications for OC in the future.
International Journal of Oncology | 2013
Petr Vaňhara; Peter Horak; Dietmar Pils; Mariam Anees; Michaela Petz; Wolfgang Gregor; Robert Zeillinger; Michael Krainer
Consequences of deregulated protein N-glycosylation on cancer pathogenesis are poorly understood. TUSC3 is a gene with a putative function in N-glycosylation, located on the short arm of chromosome 8. This is a chromosomal region of frequent genetic loss in ovarian cancer. We established recently that the expression of TUSC3 is epigenetically decreased in epithelial ovarian cancer compared to benign controls and provides prognostic information on patient survival. Therefore, we analyzed the consequences of silenced TUSC3 expression on proliferation, invasion and migration of ovarian cell lines. In addition, we performed subcellular fractionation, co-immunofluorescence and co-immunoprecipitation experiments to establish the molecular localization of TUSC3 in ovarian cancer cells. We demonstrated that TUSC3 is localized in the endoplasmic reticulum as a subunit of the oligosaccharyltransferase complex and is capable of modulation of glycosylation patterning of ovarian cancer cells. Most importantly, silencing of TUSC3 enhances proliferation and migration of ovarian cancer cells in vitro. Our observations suggest a role for N-glycosylating events in ovarian cancer pathogenesis in general, and identify TUSC3 as a tumor suppressor gene in ovarian cancer in particular.
Cancer | 2011
Mariam Anees; Peter Horak; Ahmed El-Gazzar; Martin Susani; Georg Heinze; Paul Perco; Massimo Loda; Rosina T. Lis; Michael Krainer; William Oh
TRAIL (tumor necrosis factor related apoptosis‐inducing ligand) is involved in tumor immune surveillance and, thus, may be a potential cancer therapy. TRAIL expression in the tumor microenvironment has been shown to impact cancer survival in multiple tumor types, including ovarian cancer. We studied TRAIL expression and outcomes in patients with prostate cancer.
Expert Review of Proteomics | 2016
Muhammad Nawaz; Farah Fatima; Irina Nazarenko; Karin Ekström; Iram Murtaza; Mariam Anees; Aneesa Sultan; Luciano Neder; Giovanni Camussi; Hadi Valadi; Jeremy A. Squire; Thomas Kislinger
ABSTRACT In recent years there has been tremendous interest in both the basic biology and applications of extracellular vesicles (EVs) in translational cancer research. This includes a better understanding of their biogenesis and mechanisms of selective cargo packaging, their precise roles in horizontal communication, and their application as non-invasive biomarkers. The rapid advances in next-generation omics technologies are the driving forces for these discoveries. In this review, the authors focus on recent results of EV research in ovarian cancer. A deeper understanding of ovarian cancer-derived EVs, the types of cargo molecules and their biological roles in cancer growth, metastases and drug resistance, could have significant impact on the discovery of novel biomarkers and innovative therapeutics. Insights into the role of EVs in immune regulation could lead to novel approaches built on EV-based immunotherapy.
Peptides | 2012
Fazal Wahab; Hina Salahuddin; Mariam Anees; Jérôme Leprince; Hubert Vaudry; Manuel Tena-Sempere; Muhammad Shahab
RF-amides (RFa), a superfamily of evolutionary-conserved neuropeptides, are expressed in both invertebrates and vertebrates. While some endocrine functions have been attributed to these peptides in lower vertebrates and few mammalian models, not much is known about their actions in primates. Therefore, the present study was designed to examine the effects of peripheral administration of two recently cloned human RFa peptides, 26RFa and 43RFa, on testosterone and prolactin secretion in the adult male adult male rhesus monkey (Macaca mulatta). For control purposes, a scrambled sequence of 26RFa (Sc-26RFa) and normal saline (1ml) were injected. Three different doses of 26RFa and 43RFa (19-nmol, 38-nmol and 76-nmol) and a single dose (38-nmol) of Sc-26RFa were tested. A set of four chair-restraint habituated monkeys was used. Comparison of post-treatment T levels with respective pre levels showed that none of the doses of both 26RFa and 43RFa changed T release. Similarly, Sc-26RFa and saline administration also did not affect T levels. In contrast, all doses of 26RFa and 43RFa significantly (P<0.05) stimulated prolactin secretion. 43RFa dose dependently increased prolactin secretion while dose dependency was not observed for 26RFa. Saline and Sc-26RFa injection had no effect on prolactin concentrations. Thus, present study demonstrated that peripheral administration of 26RFa and 43RFa, in the doses tested, have no effect on T secretion, suggesting possible selective lack of their neuroendocrine role in controlling hypothalamic-pituitary-gonadal axis in the adult male primates. The prominent stimulation of prolactin suggests a neuroendocrine role of RFa peptides in regulation of prolactin release in primates.
Science of The Total Environment | 2016
Aqib Hassan Ali Khan; Mariam Anees; Muhammad Arshad; Yousaf Shad Muhammad; Mazhar Iqbal; Sohail Yousaf
Bacterial photophysiology was previously limited to photoautotrophs. The discovery of bacteriophytochromes in non-photoautotrophs raised a question whether these non-photoautotrophs are affected by the presence or absence of light? In this research work for the first time, bacterial hydrocarbon degradation and biomass production was studied under the influence of nutrients, illuminance (light flux) and time. An experimental model was designed, with six isolated bacterial strains (Pseudomonas poae BA1, Pseudomonas rhizosphaerae BP3, Bacillus thuringiensis BG3, Acinetobacter bouvetii BP18, Pseudomonas proteolytica BG31 and Stenotrophomonas rhizophila BG32) under four different conditions of nutrient media and illuminance at three time intervals of 15, 30, and 45days without shaking. All strains showed statistically higher hydrocarbon degradation under nutrient rich, dark conditions. Highest biodegradation (80.8, 79.4, and 78.7mg) was observed in BG31, BG17 and BG3 respectively. Nutrient rich media along with dark conditions improved the biomass production, and when media was nutrient deprived, higher biomass was produced in the presence of light. This work proved that light and nutrients significantly affect bacterial populations and hydrocarbon degradation. The optimal use of these parameters could facilitate to achieve the goal of remediation of hydrocarbon contaminated sites.